334 related articles for article (PubMed ID: 25785645)
1. Targeting α-synuclein oligomers by protein-fragment complementation for drug discovery in synucleinopathies.
Moussaud S; Malany S; Mehta A; Vasile S; Smith LH; McLean PJ
Expert Opin Ther Targets; 2015 May; 19(5):589-603. PubMed ID: 25785645
[TBL] [Abstract][Full Text] [Related]
2. Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies.
Sengupta U; Guerrero-Muñoz MJ; Castillo-Carranza DL; Lasagna-Reeves CA; Gerson JE; Paulucci-Holthauzen AA; Krishnamurthy S; Farhed M; Jackson GR; Kayed R
Biol Psychiatry; 2015 Nov; 78(10):672-83. PubMed ID: 25676491
[TBL] [Abstract][Full Text] [Related]
3. Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies.
Ferrer I; Blanco R; Carmona M; Puig B; Barrachina M; Gómez C; Ambrosio S
J Neural Transm (Vienna); 2001; 108(12):1383-96. PubMed ID: 11810403
[TBL] [Abstract][Full Text] [Related]
4. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
[TBL] [Abstract][Full Text] [Related]
5. Alpha-Synuclein oligomerization and aggregation: All models are useful but only if we know what they model: This is the reply to a comment "Alpha-synuclein oligomerization and aggregation: A model will always be a model" on the original article "Monitoring alpha-synuclein oligomerization and aggregation using bimolecular fluorescence complementation assays: What you see is not always what you get". The articles are accompanied by a Preface "How good are cellular models?".
Lashuel HA
J Neurochem; 2021 May; 157(4):891-898. PubMed ID: 33336386
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
Lee VM; Trojanowski JQ
Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
[TBL] [Abstract][Full Text] [Related]
7. In Vivo Protein Complementation Demonstrates Presynaptic α-Synuclein Oligomerization and Age-Dependent Accumulation of 8-16-mer Oligomer Species.
Kiechle M; von Einem B; Höfs L; Voehringer P; Grozdanov V; Markx D; Parlato R; Wiesner D; Mayer B; Sakk O; Baumann B; Lukassen S; Liss B; Ekici AB; Ludolph AC; Walther P; Ferger B; McLean PJ; Falkenburger BH; Weishaupt JH; Danzer KM
Cell Rep; 2019 Nov; 29(9):2862-2874.e9. PubMed ID: 31775051
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy targeting α-synuclein, with relevance for future treatment of Parkinson's disease and other Lewy body disorders.
Lindström V; Ihse E; Fagerqvist T; Bergström J; Nordström E; Möller C; Lannfelt L; Ingelsson M
Immunotherapy; 2014; 6(2):141-53. PubMed ID: 24491088
[TBL] [Abstract][Full Text] [Related]
9. Formation of toxic oligomeric alpha-synuclein species in living cells.
Outeiro TF; Putcha P; Tetzlaff JE; Spoelgen R; Koker M; Carvalho F; Hyman BT; McLean PJ
PLoS One; 2008 Apr; 3(4):e1867. PubMed ID: 18382657
[TBL] [Abstract][Full Text] [Related]
10. Anti-aggregation Effects of Phenolic Compounds on α-synuclein.
Ono K; Tsuji M; Yamasaki TR; Pasinetti GM
Molecules; 2020 May; 25(10):. PubMed ID: 32456274
[TBL] [Abstract][Full Text] [Related]
11. The Golgi-localized, gamma ear-containing, ARF-binding (GGA) protein family alters alpha synuclein (α-syn) oligomerization and secretion.
von Einem B; Eschbach J; Kiechle M; Wahler A; Thal DR; McLean PJ; Weishaupt JH; Ludolph AC; von Arnim CAF; Danzer KM
Aging (Albany NY); 2017 Jul; 9(7):1677-1697. PubMed ID: 28722658
[TBL] [Abstract][Full Text] [Related]
12. Induction of α-synuclein aggregate formation by CSF exosomes from patients with Parkinson's disease and dementia with Lewy bodies.
Stuendl A; Kunadt M; Kruse N; Bartels C; Moebius W; Danzer KM; Mollenhauer B; Schneider A
Brain; 2016 Feb; 139(Pt 2):481-94. PubMed ID: 26647156
[TBL] [Abstract][Full Text] [Related]
13. Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers.
Roberts RF; Bengoa-Vergniory N; Alegre-Abarrategui J
Methods Mol Biol; 2019; 1948():69-76. PubMed ID: 30771171
[TBL] [Abstract][Full Text] [Related]
14. Targeting α-synuclein as a therapeutic strategy for Parkinson's disease.
Lawand NB; Saadé NE; El-Agnaf OM; Safieh-Garabedian B
Expert Opin Ther Targets; 2015; 19(10):1351-60. PubMed ID: 26135549
[TBL] [Abstract][Full Text] [Related]
15. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Braithwaite SP; Stock JB; Mouradian MM
Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
[TBL] [Abstract][Full Text] [Related]
16. α-Synucleinopathy phenotypes.
McCann H; Stevens CH; Cartwright H; Halliday GM
Parkinsonism Relat Disord; 2014 Jan; 20 Suppl 1():S62-7. PubMed ID: 24262191
[TBL] [Abstract][Full Text] [Related]
17. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
Wrasidlo W; Tsigelny IF; Price DL; Dutta G; Rockenstein E; Schwarz TC; Ledolter K; Bonhaus D; Paulino A; Eleuteri S; Skjevik ÅA; Kouznetsova VL; Spencer B; Desplats P; Gonzalez-Ruelas T; Trejo-Morales M; Overk CR; Winter S; Zhu C; Chesselet MF; Meier D; Moessler H; Konrat R; Masliah E
Brain; 2016 Dec; 139(Pt 12):3217-3236. PubMed ID: 27679481
[TBL] [Abstract][Full Text] [Related]
18. [Alpha-Synuclein in blood and cerebrospinal fluid of patients with alpha-synucleinopathy].
Ono K; Yamada M
Rinsho Byori; 2014 Mar; 62(3):241-5. PubMed ID: 24800499
[TBL] [Abstract][Full Text] [Related]
19. From Yeast to Humans: Leveraging New Approaches in Yeast to Accelerate Discovery of Therapeutic Targets for Synucleinopathies.
Piotrowski JS; Tardiff DF
Methods Mol Biol; 2019; 2049():419-444. PubMed ID: 31602625
[TBL] [Abstract][Full Text] [Related]
20. Tau oligomers mediate α-synuclein toxicity and can be targeted by immunotherapy.
Gerson JE; Farmer KM; Henson N; Castillo-Carranza DL; Carretero Murillo M; Sengupta U; Barrett A; Kayed R
Mol Neurodegener; 2018 Mar; 13(1):13. PubMed ID: 29544548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
